These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Total androgen ablation: American experience. Crawford ED; Nabors WL Urol Clin North Am; 1991 Feb; 18(1):55-63. PubMed ID: 1899495 [TBL] [Abstract][Full Text] [Related]
24. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review. Du Plessis DJ Urology; 1991; 37(2 Suppl):20-4. PubMed ID: 1992599 [TBL] [Abstract][Full Text] [Related]
25. A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group. Cancer Treat Res; 1992; 59():29-40. PubMed ID: 1347692 [No Abstract] [Full Text] [Related]
26. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer. Eastham JA; Sartor O J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206 [No Abstract] [Full Text] [Related]
27. Antiandrogen monotherapy in the management of advanced prostate cancer. Kaisary AV Eur Urol; 1997; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. Grimaldi C; Bleiberg H; Gay F; Messner M; Rougier P; Kok TC; Cirera L; Cervantes A; De Greve J; Paillot B; Buset M; Nitti D; Sahmoud T; Duez N; Wils J J Clin Oncol; 1998 Feb; 16(2):411-7. PubMed ID: 9469323 [TBL] [Abstract][Full Text] [Related]
29. Nilutamide: an antiandrogen for the treatment of prostate cancer. Dole EJ; Holdsworth MT Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470 [TBL] [Abstract][Full Text] [Related]
30. Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer? Pavone-Macaluso M; Serretta V; Daricello G; Pavone C; Cacciatore M; Romano C; Cavallo N Prog Clin Biol Res; 1990; 350():149-57. PubMed ID: 2201041 [TBL] [Abstract][Full Text] [Related]
32. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet; 2000 Apr; 355(9214):1491-8. PubMed ID: 10801170 [TBL] [Abstract][Full Text] [Related]
33. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805 [TBL] [Abstract][Full Text] [Related]
34. Endocrine treatment of prostate cancer: standard treatment and new perspectives. Boccardo F; Pace M In Vivo; 1993; 7(5):423-4. PubMed ID: 8110985 [TBL] [Abstract][Full Text] [Related]
38. Design of antiandrogens and their mechanisms of action: a case study (anandron). Raynaud JP; Fiet J; Le Goff JM; Martin PM; Moguilewsky M; Ojasoo T Horm Res; 1987; 28(2-4):230-41. PubMed ID: 3331376 [TBL] [Abstract][Full Text] [Related]
39. [Cancer of the prostate: biologic bases for the use of an antiandrogen in its treatment]. Raynaud JP; Coussediere D; Moguilewsky M; Pottier J; Labrie F Bull Cancer; 1986; 73(1):36-46. PubMed ID: 3779121 [TBL] [Abstract][Full Text] [Related]
40. Nilutamide approved for metastatic prostate cancer. Am J Health Syst Pharm; 1996 Dec; 53(23):2784. PubMed ID: 8957341 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]